Association Between Metabolic-Associated Fatty Liver Disease and Obstructive Sleep Apnea: A Cross-Sectional Study
Jiefeng Huang,Lida Chen,Xiuling Li,Menglan Chen,Ting Lin,Gongping Chen
DOI: https://doi.org/10.2147/NSS.S398971
2023-03-01
Nature and Science of Sleep
Abstract:Jiefeng Huang, 1– 3, &ast Lida Chen, 4, &ast Xiuling Li, 1– 3, &ast Menglan Chen, 1– 3 Ting Lin, 1– 3 Gongping Chen 1– 3 1 Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Fujian Medical University, Fujian Medical University, Fuzhou, People's Republic of China; 2 Institute of Respiratory Disease, Fujian Medical University, Fujian Medical University, Fuzhou, People's Republic of China; 3 Department of Respiratory and Critical Care Medicine, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, People's Republic of China; 4 Department of Respiratory and Critical Care Medicine, Zhangzhou Affiliated Hospital of Fujian Medical University, Xiangcheng, Zhangzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Gongping Chen, Tel/Fax +86591-87981697, Email Aim: Emerging evidence has revealed that obstructive sleep apnea (OSA) is an independent risk factor for the development of a variety of adverse metabolic disease states. In this study, we evaluated the association between OSA severity and metabolic dysfunction-associated fatty liver disease (MAFLD) among Asian populations. Materials and Methods: This was a cross-sectional, single-center study. The study cohort consisted of patients undergoing polysomnography and abdominal ultrasonography. Logistic regression analysis was used to evaluate the independent risk factors of MAFLD in patients with OSA. Results: A total of 1065 patients (277 non-MAFLD and 788 MAFLD) were included in the study. The prevalence of MAFLD in non-OSA, mild-moderate OSA, and severe OSA patients was 58.16%, 72.41%, and 78.0%, respectively ( p < 0.001). We identified significant differences in body mass index (BMI), apnea-hypopnea index (AHI), oxygen desaturation index (ODI), and lowest O 2 saturation (LaSO 2 ) between non-MAFLD and MAFLD patients (all p < 0.001). After adjusting for confounding variables, we used multivariate regression analysis to show that BMI, ODI, and triglyceride (TG) levels independently predicted the occurrence of MAFLD (odds ratio [OR] = 1.234, p < 0.001; OR = 1.022, p = 0.013; OR = 1.384, p = 0.001, respectively). Moreover, stratified analysis according to BMI indicated that TG levels were the predominant risk factor for MAFLD in a group of patients with a BMI < 23 kg/m 2 , while BMI, ODI, TG levels, and total cholesterol (TC) were the major risk factors for MAFLD in a group of patients with a BMI ≥ 23 kg/m 2 (all p < 0.05). Conclusion: OSA-associated chronic intermittent hypoxia was independently associated with the risk of MAFLD, especially in OSA patients with a BMI ≥ 23 kg/m 2 , suggesting that oxidative stress might play an important role in the pathogenesis of MAFLD in patients with OSA. Keywords: obstructive sleep apnea, chronic intermittent hypoxia, metabolic dysfunction-associated fatty liver disease, obesity Obstructive sleep apnea (OSA) is an increasingly common disorder that is characterized by periodic collapse of the upper airway, with consequent hypoxia or arousals during sleep. It has been reported that globally 936 million adults aged 30–69 may have mild to severe OSA, and 425 million may have moderate to severe OSA. 1 Evidence has shown that OSA can contribute to the development of cardiovascular diseases, resulting in an increase in morbidity and mortality rates, and a decrease in quality-of-life scores. 2–4 Metabolic abnormalities (such as obesity, hyperglycemia, dyslipidemia, and the metabolic syndrome) are associated with cardiovascular disease. OSA is strongly associated with obesity, insulin resistance, type two diabetes (T2DM), nonalcoholic fatty liver disease (NAFLD), and other related metabolic diseases; 5 therefore, OSA may exacerbate the cardiometabolic risk associated with these metabolic abnormalities. 6 Lipid peroxidation, induced by chronic intermittent hypoxia (CIH), results in the increased production of reactive oxygen species, which leads to hepatic inflammation and fibrosis, resulting in nonalcoholic steatohepatitis. 7 During the 2000s, evidence emerged that linked OSA severity with the development and progression of NAFLD. For example, CIH (a hallmark of OSA) was identified as an independent risk factor in the onset and progression of NAFLD. 7 The essential links between CIH and NAFLD involve insulin resistance, glucose dysregulation, dysfunction of key steps in hepatic lipid -Abstract Truncated-
neurosciences,clinical neurology